S-adenosyl-l-methionine (SAMe) for smoking abstinence: A randomized clinical trial

Journal of Alternative and Complementary Medicine

Volumn 18, Issue 9, 2012, Pages 854-859

  Sood, Amit ^a   Prasad, Kavita ^a   Croghan, Ivana T ^a   Schroeder, Darrell R ^a   Ehlers, Shawna L ^a   Ebbert, Jon O ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; NATURE MADE; S ADENOSYLMETHIONINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABSTINENCE; ADULT; ARTICLE; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; EXPIRED AIR; FEMALE; HEALTH BEHAVIOR; HUMAN; MALE; PATIENT COMPLIANCE; PATIENT COUNSELING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; BREATH TESTS; CARBON MONOXIDE; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; PATIENT DROPOUTS; S-ADENOSYLMETHIONINE; SELF REPORT; SMOKING; SMOKING CESSATION; TOBACCO PRODUCTS; YOUNG ADULT;

EID: 84865596298     PISSN: 10755535     EISSN: 15577708     Source Type: Journal    
DOI: 10.1089/acm.2011.0462     Document Type: Article

References (27)

1. Centers for Disease Control and Prevention. Vital Signs: Current Cigarette Smoking Among Adults aged ≥ 18 years-United States, 2009. MMWR Morb Mortal Wkly Rep 2010;59:1135-1140.
2. U.S. Department of Health and Human Services. Healthy People 2020-Improving the Health of Americans. 2020 Topics & Objectives. 2010. Online document at: www.healthypeople.gov/2020/default.aspx Accessed March 15, 2011.
3. Hoogendoorn M, Feenstra TL, Hoogenveen RT, Rutten-van Molken MP. Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. Thorax 2010;65:711-718.
4. Bottiglieri T. S-Adenosyl-L-methionine (SAMe): From the bench to the bedside. Molecular basis of a pleiotrophic molecule. Am J Clin Nutr 2002;76:1151S-1157S.
5. Otero-Losada ME, Rubio MC. Acute changes in 5-HT metabolism after S-adenosyl-L-methionine administration. Gen Pharmacol 1989;20:403-406.
6. Losada ME, Rubio MC. Acute effects of S-adenosyl-Lmethionine on catecholaminergic central function. Eur J Pharmacol 1989;163:353-356.
7. Rosenbaum JF, Fava M, Falk WE, et al. The antidepressant potential of oral S-adenosyl-l-methionine. Acta Psychiatr Scand 1990;81:432-436.
8. Bottiglieri T, Hyland K, Reynolds EH. The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. Drugs 1994;48:137-152.
9. Papakostas GI, Mischoulon D, Shyu I, et al. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: A double-blind, randomized clinical trial. Am J Psychiatry 2010;167:942-948.
10. Genedani S, Saltini S, Benelli A, et al. Influence of SAMe on the modifications of brain polyamine levels in an animal model of depression. Neuroreport 2001;12:3939-3942.
11. Saletu B, Anderer P, Di Padova C, et al. Electrophysiological neuroimaging of the central effects of S-adenosyl-L-methionine by mapping of electroencephalograms and eventrelated potentials and low-resolution brain electromagnetic tomography. Am J Clin Nutr 2002;76:1162S-1171S.
12. Arnold O, Saletu B, Anderer P, et al. Double-blind, placebocontrolled pharmacodynamic studies with a nutraceutical and a pharmaceutical dose of ademetionine (SAMe) in elderly subjects, utilizing EEG mapping and psychometry. Eur Neuropsychopharmacol 2005;15:533-543.
13. Hardy M, Coulter I, Favreau J, et al. S-Adenosyl-L-Methionine for Treatment of Depression, Osteoarthritis, and Liver Disease. Rockville, MD: Agency for Healthcare Research and Quality, 2002.
14. Radloff LS. The CES-D Scale: A self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385-401.
15. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: A revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991; 86:1119-1127.
16. Biener L, Abrams DB. The Contemplation Ladder: Validation of a measure of readiness to consider smoking cessation. Health Psychol 1991;10:360-365.
17. Hughes J. Minnesota Nicotine Withdrawal Scale-Revised. 2007. Online document at: www.uvm.edu/~hbpl/?Page= minnesota/default.html Accessed March 1, 2011.
18. Hughes Jr. Effects of abstinence from tobacco: Valid symptoms and time course. Nicotine Tob Res 2007;9: 315-327.
19. Hughes J, Hatsukami DK. Errors in using tobacco withdrawal scale. Tob Control 1998;7:92-93.
20. Hughes JR, Keely JP, Niaura RS, et al. Measures of abstinence in clinical trials: Issues and recommendations. Nicotine Tob Res 2003;5:13-25.
21. Ratain MJ, Sargent DJ. Optimising the design of phase II oncology trials: The importance of randomisation. Eur J Cancer 2009;45:275-280.
22. Rubinstein LV, Korn EL, Freidlin B, et al. Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 2005;23:7199-7206.
23. Hays JT, Ebbert JO. Bupropion sustained release for treatment of tobacco dependence. Mayo Clin Proc 2003;78:1020- 1024; quiz 1024.
24. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 2010;63:e1-37.
25. Papakostas GI, Alpert JE, Fava M. S-adenosyl-methionine in depression: A comprehensive review of the literature. Curr Psychiatry Rep 2003;5:460-466.
26. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. JAMA 2006;296:56-63.
27. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA 2006;296: 47-55.